Drug Treatment for Multidrug-resistant Acinetobacter baumannii Infections

Matteo Bassetti; Elda Righi; Silvano Esposito; Nicola Petrosillo; Laura Nicolini

Disclosures

Future Microbiol. 2008;3(6):649-660. 

In This Article

Abstract and Introduction

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging pathogen in healthcare settings, where it causes infections that include bacteremia, pneumonia, meningitis, and urinary tract and wound infections. Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to the carbapenems. Other therapeutic options include sulbactam, aminoglycosides, polymixyns and tigecycline. The discovery of new therapies coupled with the development of controlled clinical trial antibiotic testing combinations and the prevention of transmission of MDR Acinetobacter infection are essential to face this important hospital problem.

Acinetobacter baumannii is a ubiquitous pathogen that has emerged in the last few decades as a major cause of healthcare-associated infections (HAIs) and nosocomial outbreaks.[1]A. baumannii's capability to replicate in the hospital environment is facilitated both by tolerance to desiccation and multidrug resistance, the latter also favoring endemic infections through antibiotic-selective pressure.[2] Multidrug-resistant (MDR) A. baumannii is a rapidly emerging pathogen in the healthcare setting, where it causes infections that include bacteremia, pneumonia, meningitis, urinary tract infection and wound infection. Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to carbapenems. Other therapeutic options include ß-lactamase inhibitors, aminoglycosides, polymixyn and tigecycline.[3] The discovery of new therapies coupled with the development of controlled clinical trials on antibiotics combinations and the prevention of the transmission of MDR Acinetobacter infection are essential to face this important hospital problem. The epidemiology and the risk factors related to MDR A. baumannii infections, as well as the currently therapeutic options are revised in this article.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....